Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948 | 1.00 | MPI (0.36) | MPIUSP2SLCO1B1PAX8LMNA | |
| SCHEMBL7155133 | 1.00 | MPI (0.36) | MPIUSP2SLCO1B1PAX8LMNA | |
| SCHEMBL181949 | 1.00 | MPI (0.36) | MPIUSP2SLCO1B1PAX8LMNA | |
| SCHEMBL10699689 | 0.88 | MPI (0.33) | MPIUSP2SLCO1B1PAX8 | |
| SCHEMBL9078408 | 0.88 | MPI (0.33) | MPIUSP2SLCO1B1PAX8 | |
| SCHEMBL705391 | 0.87 | PAX8 (0.36) | MPIUSP2SLCO1B1PAX8 | |
| SCHEMBL5351083 | 0.83 | ITPR3 (0.31) | — | |
| SCHEMBL177758 | 0.83 | MPI (0.46) | MPILMNAL3MBTL1TDP1 | |
| SCHEMBL5972505 | 0.83 | MPI (0.46) | MPILMNAL3MBTL1TDP1 | |
| SCHEMBL1922060 | 0.83 | MPI (0.46) | MPILMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CEDARS-SINAI MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
| WO-2012027797-A1 | ANTI-INFLAMMATORY COMPOSTION | JAMES DAVID CHARLES (AU) | 2012-03-08 | — | — | WO | disclosed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CSGALNACT1, SLC2A8, FUT6 | MPI 38/4885USP2 3383/4885SLCO1B1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.